Our in vitro success counsel that EAM-2201 needs to be examined with regard to possible in vivo pharmacokinetic drug–drug interactions attributable to time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 things to do and aggressive inhibition of UGT1A3 activity. It seems to Exhibit a larger potency in vitro than JWH-018. https://samuela838iyn1.wikigdia.com/user